We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Read MoreHide Full Article
Key Takeaways
Inogen lowered 2026 revenue guidance to $355M-$361M as U.S. sales-channel pressure persists.
INGN's U.S. sales fell 2.3% and rental revenues dropped 11.8% in the second quarter.
Inogen's international sales rose 14.8%, while adjusted gross margin improved to 45.6%.
Inogen, Inc. (INGN - Free Report) lowered its 2026 revenue outlook after second-quarter results showed continued U.S. channel pressure despite better profitability and international growth. The revision puts more focus on how quickly the company can adapt its commercial model.
The key question is whether weaker direct sales and rentals mainly reflect a channel transition or a more persistent growth constraint. International demand, new products and cost control provide offsets, but execution remains important.
Inogen’s Guidance Cut Resets 2026 Expectations
Inogen now expects 2026 revenues of $355 million to $361 million, down from its previous $366 million to $373 million range. The revised midpoint implies about 3% growth from 2025.
For the third quarter, management expects revenues to be roughly in line with the year-earlier period. The outlook reflects U.S. sales-channel mix pressure and the timing of select international distributor inventory purchases.
Image Source: Zacks Investment Research
INGN’s U.S. Channel Shift Drives the Pressure
The U.S. oxygen market is moving more rapidly toward portable oxygen concentrators, or POCs, as the initial therapy supplied by home medical equipment providers. That reduces the pool of patients who historically later approached Inogen directly for a portable alternative.
Second-quarter U.S. sales fell 2.3% year over year to $42.3 million, while U.S. rental revenues declined 11.8% to $11.6 million. Inogen is expanding its business-to-business effort, but direct-to-consumer pressure is expected to continue in the second half.
Inogen’s International Business Provides an Offset
International sales rose 14.8% year over year to $41.3 million in the second quarter, marking the 10th consecutive quarter of double-digit growth. Geographic expansion and deeper distributor relationships support the longer-term international strategy.
Near-term order patterns may be uneven. Management expects several distributors to manage inventories during the second half because of factors including delayed tenders and distributor consolidation, which could shift purchase timing.
Inogen has shipped more than 5,000 Voxi stationary oxygen concentrators, while Aurora CPAP mask customers more than doubled sequentially in the second quarter. These products extend the company beyond POCs while using many of the same home medical equipment relationships.
Image Source: Zacks Investment Research
Resmed Inc. (RMD - Free Report) operates across sleep and breathing health with care delivered in the home, highlighting the overlap between respiratory and sleep markets. Inspire Medical Systems, Inc. (INSP - Free Report) focuses on obstructive sleep apnea through implantable neurostimulation, another approach to sleep-related respiratory care.
Inogen’s Profitability Trend Offers Support
Adjusted gross margin improved 65 basis points year over year to 45.6% in the second quarter, helped by cost improvements and lower warranty expenses. Adjusted operating loss narrowed to $1.3 million from $2.6 million a year earlier.
Management is reviewing its cost structure to align spending with strategic priorities. That discipline could support profitability while Inogen invests in business-to-business selling, product development, clinical programs and international expansion.
Image Source: Zacks Investment Research
INGN’s Signals Reflect Mixed Near-Term Conditions
The lower revenue outlook leaves Inogen balancing international growth and product expansion against a structural shift in its U.S. direct and rental channels. Near-term progress depends on whether business-to-business gains can offset continued direct-channel erosion.
INGN currently carries a Zacks Rank #3 (Hold), with a VGM Score of C, Value Score of C, Growth Score of D and Momentum Score of A. The Rank points to a neutral short-term earnings-revision backdrop, while the Style Scores show favorable momentum but weaker growth characteristics and middling value and combined readings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Style Scores are designed to complement the Zacks Rank, so the combination does not provide a uniformly positive or negative signal. The coming quarters should offer clearer evidence on channel adaptation, distributor timing and contributions from newer respiratory products.
View the Zacks #1 Rank List
Image: Bigstock
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Key Takeaways
Inogen, Inc. (INGN - Free Report) lowered its 2026 revenue outlook after second-quarter results showed continued U.S. channel pressure despite better profitability and international growth. The revision puts more focus on how quickly the company can adapt its commercial model.
The key question is whether weaker direct sales and rentals mainly reflect a channel transition or a more persistent growth constraint. International demand, new products and cost control provide offsets, but execution remains important.
Inogen’s Guidance Cut Resets 2026 Expectations
Inogen now expects 2026 revenues of $355 million to $361 million, down from its previous $366 million to $373 million range. The revised midpoint implies about 3% growth from 2025.
For the third quarter, management expects revenues to be roughly in line with the year-earlier period. The outlook reflects U.S. sales-channel mix pressure and the timing of select international distributor inventory purchases.
Image Source: Zacks Investment Research
INGN’s U.S. Channel Shift Drives the Pressure
The U.S. oxygen market is moving more rapidly toward portable oxygen concentrators, or POCs, as the initial therapy supplied by home medical equipment providers. That reduces the pool of patients who historically later approached Inogen directly for a portable alternative.
Second-quarter U.S. sales fell 2.3% year over year to $42.3 million, while U.S. rental revenues declined 11.8% to $11.6 million. Inogen is expanding its business-to-business effort, but direct-to-consumer pressure is expected to continue in the second half.
Inogen’s International Business Provides an Offset
International sales rose 14.8% year over year to $41.3 million in the second quarter, marking the 10th consecutive quarter of double-digit growth. Geographic expansion and deeper distributor relationships support the longer-term international strategy.
Near-term order patterns may be uneven. Management expects several distributors to manage inventories during the second half because of factors including delayed tenders and distributor consolidation, which could shift purchase timing.
Inogen, Inc Price and Consensus
Inogen, Inc price-consensus-chart | Inogen, Inc Quote
INGN’s New Products Could Broaden Growth
Inogen has shipped more than 5,000 Voxi stationary oxygen concentrators, while Aurora CPAP mask customers more than doubled sequentially in the second quarter. These products extend the company beyond POCs while using many of the same home medical equipment relationships.
Image Source: Zacks Investment Research
Resmed Inc. (RMD - Free Report) operates across sleep and breathing health with care delivered in the home, highlighting the overlap between respiratory and sleep markets. Inspire Medical Systems, Inc. (INSP - Free Report) focuses on obstructive sleep apnea through implantable neurostimulation, another approach to sleep-related respiratory care.
Inogen’s Profitability Trend Offers Support
Adjusted gross margin improved 65 basis points year over year to 45.6% in the second quarter, helped by cost improvements and lower warranty expenses. Adjusted operating loss narrowed to $1.3 million from $2.6 million a year earlier.
Management is reviewing its cost structure to align spending with strategic priorities. That discipline could support profitability while Inogen invests in business-to-business selling, product development, clinical programs and international expansion.
Image Source: Zacks Investment Research
INGN’s Signals Reflect Mixed Near-Term Conditions
The lower revenue outlook leaves Inogen balancing international growth and product expansion against a structural shift in its U.S. direct and rental channels. Near-term progress depends on whether business-to-business gains can offset continued direct-channel erosion.
INGN currently carries a Zacks Rank #3 (Hold), with a VGM Score of C, Value Score of C, Growth Score of D and Momentum Score of A. The Rank points to a neutral short-term earnings-revision backdrop, while the Style Scores show favorable momentum but weaker growth characteristics and middling value and combined readings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Style Scores are designed to complement the Zacks Rank, so the combination does not provide a uniformly positive or negative signal. The coming quarters should offer clearer evidence on channel adaptation, distributor timing and contributions from newer respiratory products.